Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2014

01-09-2014 | Skeletal Genetics (ML Johnson and S Ralston, Section Editors)

Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments

Authors: Igor Fijalkowski, Eveline Boudin, Geert Mortier, Wim Van Hul

Published in: Current Osteoporosis Reports | Issue 3/2014

Login to get access

Abstract

Sclerosing bone dysplasias are a group of rare, monogenic disorders characterized by increased bone density resulting from the disturbance in the fragile equilibrium between bone formation and resorption. Over the last decade, major contributions have been made toward better understanding of the pathogenesis of these conditions. These studies provided us with important insights into the bone biology and yielded the identification of numerous drug targets for the prevention and treatment of osteoporosis. Here, we review this heterogeneous group of disorders focusing on their utility in the development of novel osteoporosis therapies.
Literature
1.
2.
Ferrari S. Human genetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2008;22(5):723–35.PubMedCrossRef
3.
Kornak U et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet. 2000;9(13):2059–63.PubMedCrossRef
4.•
Sobacchi C et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol. 2013;9(9):522–36. Comprehensive and up-to-date review on the heterogeneous group of Osteopetroses.PubMedCrossRef
5.
Kornak U et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205–15.PubMedCrossRef
6.
Chalhoub N et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med. 2003;9:399–406.PubMedCrossRef
7.
Sly WS et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985;313:139–45.PubMedCrossRef
8.
Guerrini MM et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83(1):64–76.PubMedCentralPubMedCrossRef
9.
Sobacchi C et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39(8):960–2.PubMedCrossRef
10.
Smahi A et al. The NF-kappaB signaling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11(20):2371–5.PubMedCrossRef
11.
Van Wesenbeeck L et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117(4):919–30.PubMedCentralPubMedCrossRef
12.
Aker M et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet. 2012;49(4):221–6.PubMedCrossRef
13.
Cleiren E et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;10(25):2861–7.PubMedCrossRef
14.
Bollerslev J et al. Autosomal dominant osteopetrosis revisited: lessons from recent studies. Eur J Endocrinol. 2013;169(2):R39–57.PubMedCrossRef
15.
Gelb BD et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236–8.PubMedCrossRef
16.
Little RD et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11–9.PubMedCentralPubMedCrossRef
17.
Boyden LM et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.PubMedCrossRef
18.
19.
Balemans W et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–43.PubMedCrossRef
20.
Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89.PubMedCentralPubMedCrossRef
21.
22.
23.
Kim SJ et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011;129(5):497–502.PubMedCrossRef
24.
Jenkins ZA et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41(1):95–100.PubMedCrossRef
25.
Nurnberg P et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, results in craniometaphyseal dysplasia. Nat Genet. 2001;28(1):37–41.PubMed
26.
Reichenberger E et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321–6.PubMedCentralPubMedCrossRef
27.
28.
Janssens K et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26(3):273–5.PubMedCrossRef
29.
Kinoshita A et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26(1):19–20.PubMedCrossRef
30.
Hellemans J et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004;36(11):1213–8.PubMedCrossRef
31.
Mumm S et al. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2007;22(2):243–50.PubMedCrossRef
32.
Ababneh FK et al. Hereditary deletion of the entire FAM20C gene in a patient with Raine syndrome. Am J Med Genet A. 2013;161A(12):3155–60.PubMedCrossRef
33.
34.
Singer FR, Mills BG. Evidence for a viral etiology of Paget's disease of bone. Clin Orthop Relat Res. 1983;178:245–51.PubMed
35.
36.
Hocking LJ et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet. 2002;11(22):2735–9.PubMedCrossRef
37.
38.
Whyte MP et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175–84.PubMedCrossRef
39.
Hughes AE et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45–8.PubMedCrossRef
40.
Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17(1):26–9.PubMedCrossRef
41.
Whyte MP et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J Bone Miner Res. 2000;15(12):2330–44.PubMedCrossRef
42.
Boudin E et al. No mutations in the serotonin related TPH1 and HTR1B genes in patients with monogenic sclerosing bone disorders. Bone. 2013;55(1):52–6.PubMedCrossRef
43.
Boudin E et al. Mutations in sFRP1 or sFRP4 are not a common cause of craniotubular hyperostosis. Bone. 2013;52(1):292–5.PubMedCrossRef
44.
45.••
Lazarus S, Zankl A, Duncan EL. Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery. Osteoporos Int. 2014;25(2):407–22. Reviews the insights into Sclerosing Bone Dysplasias provided by novel sequencing techniques.PubMedCrossRef
46.
Borra VM et al. Localization of the gene for hyperostosis cranialis interna to chromosome 8p21 with analysis of three candidate genes. Calcif Tissue Int. 2013;93(1):93–100.PubMedCrossRef
47.
Borra VM et al. Localization of the gene for X-linked calvarial hyperostosis to chromosome Xq27.3-Xqter. Bone. 2014;58:67–71.PubMedCrossRef
48.
Pagon RA, Beckwith JB, Ward BH. Calvarial hyperostosis: a benign X-linked recessive disorder. Clin Genet. 1986;29(1):73–8.PubMedCrossRef
49.
Zhang Y et al. Novel and recurrent germline LEMD3 mutations causing Buschke-Ollendorff syndrome and osteopoikilosis but not isolated melorheostosis. Clin Genet. 2009;75(6):556–61.PubMedCrossRef
50.
Kasapkara CS et al. An extremely rare case: osteosclerotic metaphyseal dysplasia. Genet Couns. 2013;24(1):69–74.PubMed
51.
52.
Das S, Crockett JC. Osteoporosis - a current view of pharmacologic prevention and treatment. Drug Des Devel Ther. 2013;7:435–48.PubMedCentralPubMed
53.
Leder BZ, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694–700.
54.
Schaller S et al. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res. 2004;19(7):1144–53.PubMedCrossRef
55.
Qin A et al. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol. 2012;44(9):1422–35.PubMedCrossRef
56.
Saftig P et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A. 1998;95(23):13453–8.PubMedCentralPubMedCrossRef
57.
58.
Langdahl B et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res. 2012;27(11):2251–8.PubMedCrossRef
59.
Sims NA, Ng KW. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Curr Osteoporos Rep. 2014;12(1):98–106.PubMedCrossRef
60.
Chen M et al. Emerging therapeutic targets for osteoporosis treatment. Expert Opin Ther Target. 2014;18(7):817–831.
61.
Ng KW, Martin TJ. New therapeutics for osteoporosis. Curr Opin Pharmacol. 2014;16C:58–63.CrossRef
62.
Boudin E et al. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum. 2013;43(2):220–40.PubMedCrossRef
63.••
McClung MR et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. The most recent report on the clinical trials of the most promising osteoporosis treatment in development.PubMedCrossRef
64.
Kedlaya R et al. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome. Sci Transl Med. 2013;5(211):211ra158.PubMedCentralPubMedCrossRef
65.•
Sinder BP et al. Sclerostin antibody improves skeletal parameters in a Brtl/+mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73–80. Supports the therapeutic effect of sclerostin antibody in murine model of Osteogenesis Imperfecta. Demonstrates the diversity of this therapeutic agent.PubMedCentralPubMedCrossRef
66.•
Chang MK et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. 2014;29(1):29–42. Comprehensive studies providing insights into the biology of sclerostin inhibition. PubMedCrossRef
67.
van Lierop AH et al. Serum Dickkopf 1 levels in sclerostin deficiency. J Clin Endocrinol Metab. 2014;99(2):E252–6.PubMedCrossRef
68.
Morvan F et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934–45.PubMedCrossRef
69.
Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg Med Chem. 2010;18(1):190–201.PubMedCrossRef
70.
Moore WJ et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides. J Med Chem. 2009;52(1):105–16.PubMedCrossRef
Metadata
Title
Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments
Authors
Igor Fijalkowski
Eveline Boudin
Geert Mortier
Wim Van Hul
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 3/2014
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-014-0220-5

Other articles of this Issue 3/2014

Current Osteoporosis Reports 3/2014 Go to the issue

Pediatrics (M Leonard and L Ward, Section Editors)

The Epidemiology of Fractures in Otherwise Healthy Children

Pediatrics (M Leonard and L Ward, Section Editors)

Fractures in Children with Cerebral Palsy

Bone Quality in Osteoporosis (MD Grynpas and JS Nyman, Section Editors)

The Role of Nanoscale Toughening Mechanisms in Osteoporosis

Bone Quality in Osteoporosis (MD Grynpas and JS Nyman, Section Editors)

Changes in the Degree of Mineralization with Osteoporosis and its Treatment

Pediatrics (M Leonard and L Ward, Section Editors)

Bone Morbidity in Childhood Leukemia: Epidemiology, Mechanisms, Diagnosis, and Treatment

Hot Topic

Aneuploidy and Skeletal Health